AbbVie Inc. (ABBV)
| Previous close | 167.80 |
| Open | 167.66 |
| Bid | 166.72 x 800 |
| Ask | 166.78 x 800 |
| Day's range | 165.59 - 169.14 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,617,229 |
| Market cap | 295.362B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 61.33 |
| EPS (TTM) | 2.72 |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | 6.20 (3.69%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | 184.70 |
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
ZacksZacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
PR NewswireNew Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
AbbVie (NYSE: ABBV) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib (RINVOQ®, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (DUPIXENT®, per its labeled dose) in adults and adolescents (≥12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of th
